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Accepted 8 April 2015Donor availability for allogeneic hematopoietic cell
transplantation (HCT) has been an area of intensive research
for many years. The aim has been to close the gap in donor
availability for those patients who require a potentially
curative allogeneic HCT but lack a suitable HLA-matched
sibling donor, the “gold standard” of the allogeneic donors.
As most hematological malignancies occur in adults in their
ﬁfth decade of life and beyond, there was a signiﬁcant unmet
need for alternative donors for this patient population in
which an HLA-matched sibling may not be clinically suitable
to donate.
Until the late 1990s, adult unrelated donors were the
main alternative donor type for HCT, with the matched un-
related donor (MUD) becoming the “gold standard of alter-
native donors.” Currently, Bone Marrow Donors Worldwide
has over 25 million potential donors registered (http://
www.bmdw.org/). Despite this large number, about one third
of Caucasian and a larger proportion of minorities will not
ﬁnd a MUD in the registries [1]. The ability to ﬁnd a donor
increases if HLA-mismatched unrelated donors are consid-
ered. Although a single-locus HLA-mismatched unrelated
donor (misMUD) may be well tolerated, greater degrees of
HLA mismatch are associated with higher risks of graft-
versus-host disease (GVHD) and death.
In the late 1990s, cord blood (CB) emerged as yet another
potential alternative donor source for HCT [2-4]. The better
tolerance of HLA mismatches and the rapid availability of CB
positioned it as a valuable donor type to further close the
donor availability gap and allow faster time to trans-
plantation in high-risk patients. Although CB was initially
restricted to children because of the limited cell dose in in-
dividual units, better understanding of cell dose re-
quirements and technical advances, such as double CB
transplantation, broadened its use to adults.Financial disclosure: See Acknowledgments on page 958.
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Malard et al. reported on the outcomes of CB compared
with MUD and misMUD after reduced-intensity or non-
myeloablative conditioning [5]. Although we could be temp-
ted to dissect differences in patient populations to explain
their effect, or lack thereof, on the results, themessagewould
not change. Themain observation of this study is that despite
differences in the risk of complications (eg, such as graft
failure and GVHD) and patterns of failure (eg, nonrelapse
mortality and relapse), survival was similar for all 3 donor
types. This study, which was conducted using more stringent
HLA matching for MUD and misMUD (10 alleles), conﬁrms a
previous report by the Center for International Blood and
Marrow Transplant Research in a similar setting [6].
For many years, CB has enjoyed prominence as the go-to
alternative donor type for those who lack a MUD. The study
of Malard et al. included patients treated between 2002 and
2010, reﬂecting the era of rapid growth in use of CB [5]. Along
with the growth in utilization, several groups and in-
stitutions started studies that have improved the safety and
efﬁcacy of CB transplantation, in particular by targeting the
slower and lower engraftment rates compared withmatched
sibling donor andMUD as shown in theMalard et al. data [5].
These studies to improve homing or ex vivo expansion of
progenitor cells are ongoing. Although a robust new strategy
could improve the efﬁcacy of CB transplantation, most are
not yet ready for prime time and their technical re-
quirements limit widespread utilization.
Not addressed in the study by Malard et al. [5] is the fact
that there is a “new kid on the block,” the unmodiﬁed
partially HLA-matched related donor (haplo-identical) bone
marrow with post-transplantation cyclophosphamide
(pTCy) as GVHD prophylaxis [7]. This new strategy for an old
donor type has been rapidly growing, especially in regions
where access to the unrelated donor or CB pool is limited.
Numbers of patients and follow-up in most centers and
registries are still limited, but emerging data suggest that
results of haplo-identical transplantation with pTCy yield
similar survival as MUD [8] and CB [9].
In a world where most retrospective studies show similar
outcomes between MUD, misMUD, and CB, as in the Malard
et al. study [5], and now add haplo-identical donors, how do
these data help us move the alternative donor trans-
plantation ﬁeld forward? Although there is no single answer
C.G. Brunstein / Biol Blood Marrow Transplant 21 (2015) 957e958958to this question, the ﬁrst step is to urge the development of
multicenter prospective studies. In phase 2 and phase 3
randomized studies, data collection needs to go beyond the
clinical outcome measures and should at least include
quality of life, resource utilization, and, when applicable,
studies of late effects and immune reconstitution. A good
example is the Blood and Marrow Transplant Clinical Trials
Network current multicenter phase 3 randomized trial
(1101) comparing double CB and haplo-identical donor with
pTCy (www.clinicaltrials.gov, NCT01597778) that was built
upon 2 parallel prospective phase 2 studies [9] that were
developed from promising single-center experiences [7,10].
A second step would include the centers committed and
able to test new methodologies to improve all options
including not only CB, but MUD, misMUD, and haplo-
identical donors in phase 1 and 2 studies. A third step
would be to continue large retrospective studies like that by
Malard et al. [5], which will highlight areas needing
improvement and generate new hypothesis to be tested.
The Societé Farncaise de Greffe de Moelle et de Thérapie
Cellulaire that sponsored the study by Malard et al. maybe
uniquely positioned to conduct such large phase 2 and 3
studies. As patterns of treatment failure differ between do-
nors types, the single payer system in France may allow for
unique observations on the early versus late cost effective-
ness of the different donor types, as recently published [11].
Now that we know we can ﬁnd a donor for virtually every
patient who needs an allogeneic HCT, large prospective multi-
center studies will help disseminate technology, leading to
better care and, ultimately, better outcomes for all our patients.
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